BTIG analyst Thomas Shrader raised his price target on Esperion to $90 and kept his Buy rating going into this week's PDUFA deadline for its bempedoic acid, or BA. The analyst says his discussions with non-coastal lipidologists are keeping him excited about the "very high" price potential of the drug, though he sees the price as "not particularly patient-driven" but rather by payors who can make a drug like BA hard to get.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here